miRNA Expression Profiles in Ovarian Endometriosis and Two Types of Ovarian Cancer—Endometriosis-Associated Ovarian Cancer and High-Grade Ovarian Cancer
Abstract
:1. Introduction
2. Results
2.1. Patients’ Clinical and Histopathological Characteristics
2.2. miRNA Expression
The miRNA Enrichment Analysis and Annotation Tool
3. Discussion
4. Materials and Methods
4.1. Preparation of Tissue Samples
4.2. RNA Extraction from FFPE Samples
4.3. Determinations of the miRNA Gene Expression Profile
4.4. RT-qPCR with Individual cDNA
4.5. MicroRNA Assays
4.6. miRNA Enrichment Analysis and Annotation Tool
4.7. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Giudice, L.C.; Kao, L.C. Endometriosis. Lancet 2004, 364, 1789–1799. [Google Scholar] [CrossRef]
- Chapron, C.; Marcellin, L.; Borghese, B.; Santulli, P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat. Rev. Endocrinol. 2019, 15, 666–682. [Google Scholar] [CrossRef]
- Taylor, H.S.; Kotlyar, A.M.; Flores, V.A. Endometriosis is a chronic systemic disease: Clinical challenges and novel innovations. Lancet 2021, 397, 839–852. [Google Scholar] [CrossRef]
- Márki, G.; Vásárhelyi, D.; Rigó, A.; Kaló, Z.; Ács, N.; Bokor, A. Challenges of and possible solutions for living with endometriosis: A qualitative study. BMC Womens Health 2022, 22, 20. [Google Scholar] [CrossRef] [PubMed]
- Haraguchi, H.; Koga, K.; Takamura, M.; Makabe, T.; Sue, F.; Miyashita, M.; Urata, Y.; Izumi, G.; Harada, M.; Hirata, T.; et al. Development of ovarian cancer after excision of endometrioma. Fertil. Steril. 2016, 106, 1432–1437.e2. [Google Scholar] [CrossRef] [PubMed]
- Murakami, K.; Kotani, Y.; Shiro, R.; Takaya, H.; Nakai, H.; Matsumura, N. Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts. Int. J. Clin. Oncol. 2020, 25, 51–58. [Google Scholar] [CrossRef] [PubMed]
- Anglesio, M.S.; Papadopoulos, N.; Ayhan, A.; Nazeran, T.M.; Noë, M.; Horlings, H.M.; Lum, A.; Jones, S.; Senz, J.; Seckin, T.; et al. Cancer-Associated Mutations in Endometriosis without Cancer. N. Engl. J. Med. 2017, 376, 1835–1848. [Google Scholar] [CrossRef]
- Lowery, W.J.; Schildkraut, J.M.; Akushevich, L.; Bentley, R.; Marks, J.R.; Huntsman, D.; Berchuck, A. Loss of ARID1A -Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers. Int. J. Gynaecol. Cancer 2012, 22, 9–14. [Google Scholar] [CrossRef]
- Hájková, N.; Tichá, I.; Hojný, J.; Němejcová, K.; Bártů, M.; Michálková, R.; Zikán, M.; Cibula, D.; Laco, J.; Geryk, T.; et al. Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases. Oncol. Lett. 2019, 17, 2207–2214. [Google Scholar] [CrossRef]
- Huang, C.Y.; Chang, W.H.; Huang, H.Y.; Guo, C.Y.; Chou, Y.J.; Huang, N.; Lee, W.L.; Wang, P.H. Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumour: A Population-Based Cohort Study. Clin. Epidemiol. 2020, 12, 637–649. [Google Scholar] [CrossRef]
- Yang, S.T.; Chang, W.H.; Lee, N.R.; Lai, W.A.; Shen, S.H.; Lee, W.L.; Wang, P.H. Endometriosis-associated epithelial ovarian cancer is a more complicated disease than we suspected before. Taiwan J. Obstet. Gynaecol. 2021, 60, 1112–1115. [Google Scholar] [CrossRef] [PubMed]
- Leng, J.; Lang, J.; Guo, L.; Li, H.; Liu, Z. Carcinosarcoma arising from atypical endometriosis in a cesarean section scar. Int. J. Gynaecol. Cancer 2006, 16, 432–435. [Google Scholar] [CrossRef] [PubMed]
- Taburiaux, L.; Pluchino, N.; Petignat, P.; Wenger, J.M. Endometriosis-Associated Abdominal Wall Cancer: A Poor Prognosis? Int. J. Gynaecol. Cancer 2015, 25, 1633–1638. [Google Scholar] [CrossRef]
- Kvaskoff, M.; Mahamat-Saleh, Y.; Farland, L.V.; Shigesi, N.; Terry, K.L.; Harris, H.R.; Roman, H.; Becker, C.M.; As-Sanie, S.; Zondervan, K.T.; et al. Endometriosis and cancer: A systematic review and meta-analysis. Hum. Reprod. Update 2021, 19, 393–420. [Google Scholar] [CrossRef] [PubMed]
- Braicu, O.L.; Budisan, L.; Buiga, R.; Jurj, A.; Achimas-Cadariu, P.; Pop, L.A.; Braicu, C.; Irimie, A.; Berindan-Neagoe, I. miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples. Onco. Targets Ther. 2017, 10, 4225–4238. [Google Scholar] [CrossRef] [PubMed]
- Marí-Alexandre, J.; Sánchez-Izquierdo, D.; Gilabert-Estellés, J.; Barceló-Molina, M.; Braza-Boïls, A.; Sandoval, J. miRNAs Regulation and Its Role as Biomarkers in Endometriosis. Int. J. Mol. Sci. 2016, 17, 93. [Google Scholar] [CrossRef] [PubMed]
- Grenda, A.; Budzyński, M.; Filip, A. Biogenesis of microRNAs and their role in the development and course of selected hematologic disorders. Postępy Hig. Med. Doświadczalnej 2013, 67, 174–185. [Google Scholar] [CrossRef]
- Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [Google Scholar] [CrossRef]
- Riley, K.J.; Yario, T.A.; Steitz, J.A. Association of Argonaute proteins and microRNAs can occur after cell lysis. RNA 2012, 18, 1581–1585. [Google Scholar] [CrossRef]
- Mogą, M.A.; Bălan, A.; Dimienescu, O.G.; Burtea, V.; Dragomir, R.M.; Anastasiu, C.V. Circulating miRNAs as Biomarkers for Endometriosis and Endometriosis-Related Ovarian Cancer-An Overview. J. Clin. Med. 2019, 23, 735. [Google Scholar] [CrossRef]
- Ferlita, A.; Battaglia, R.; Andronico, F.; Caruso, S.; Cianci, A.; Purello, M.; Pietro, C.D. Non-Coding RNAs in Endometrial Physiopathology. Int. J. Mol. Sci. 2018, 19, 2120. [Google Scholar] [CrossRef]
- Métairie, M.; Benoit, L.; Koual, M.; Bentivegna, E.; Wohrer, H.; Bolze, P.A.; Kerbage, Y.; Raimond, E.; Akladios, C.; Carcopino, X.; et al. A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer. Cancers 2023, 15, 706. [Google Scholar] [CrossRef]
- Veryaskina, Y.A.; Titov, S.E.; Ivanov, M.K.; Ruzankin, P.S.; Tarasenko, A.S.; Shevchenko, S.P.; Kovynev, I.B.; Stupak, E.V.; Pospelova, T.I.; Zhimulev, I.F. Selection of reference genes for quantitative analysis of microRNA expression in three different types of cancer. PLoS ONE 2022, 17, e0254304. [Google Scholar] [CrossRef] [PubMed]
- Costé, É.; Rouleux-Bonnin, F. The Crucial Choice of Reference Genes: Identification of MiR-191-5p for Normalization of MiRNAs Expression in Bone Marrow Mesenchymal Stromal Cell and HS27a/HS5 Cell Lines. Sci. Rep. 2020, 10, 17728. [Google Scholar] [CrossRef] [PubMed]
- Hu, Z.; Dong, J.; Wang, L.E.; Ma, H.; Liu, J.; Zhao, Y.; Tang, J.; Chen, X.; Dai, J.; Wei, Q.; et al. Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis 2012, 33, 828–834. [Google Scholar] [CrossRef] [PubMed]
- Aparicio-Puerta, E.; Hirsch, P.; Schmartz, G.P.; Kern, F.; Fehlmann, T.; Keller, A. miEAA 2023: Updates, new functional microRNA sets and improved enrichment visualizations. Nucleic Acids Res. 2023, 51, W319–W325. [Google Scholar] [CrossRef] [PubMed]
- Szubert, M.; Nowak-Glück, A.; Domańska-Senderowska, D.; Szymańska, B.; Sowa, P.; Rycerz, A.; Wilczyński, J.R. miR 31-3p Has the Highest Expression in Cesarean Scar Endometriosis. Int. J. Mol. Sci. 2022, 23, 4660. [Google Scholar] [CrossRef] [PubMed]
- Dragomir, M.P.; Mafra, A.C.P.; Dias, S.M.G.; Vasilescu, C.; Calin, G.A. Using microRNA networks to understand cancer. Int. J. Mol. Sci. 2018, 19, 1871. [Google Scholar] [CrossRef] [PubMed]
- Varga, A.; Márton, É.; Markovics, A.; Penyige, A.; Balogh, I.; Nagy, B.; Szilágyi, M. Suppressing the PI3K/AKT Pathway by miR-30d-5p Mimic Sensitizes Ovarian Cancer Cells to Cell Death Induced by High-Dose Estrogen. Biomedicines 2022, 10, 2060. [Google Scholar] [CrossRef] [PubMed]
- Yachida, N.; Yoshihara, K.; Yamaguchi, M.; Suda, K.; Tamura, R.; Enomoto, T. How Does Endometriosis Lead to Ovarian Cancer? The Molecular Mechanism of Endometriosis-Associated Ovarian Cancer Development. Cancers 2021, 13, 1439. [Google Scholar] [CrossRef]
- Lu, W.C.; Liu, C.J.; Tu, H.F.; Chung, Y.T.; Yang, C.C.; Kao, S.Y.; Chang, K.W.; Lin, S.C. miR-31 targets ARID1A and enhances the oncogenicity and stemness of head and neck squamous cell carcinoma. Oncotarget 2016, 7, 57254–57267. [Google Scholar] [CrossRef]
- Sugino, K.; Tamura, R.; Nakaoka, H.; Yachida, N.; Yamaguchi, M.; Mori, Y.; Yamawaki, K.; Suda, K.; Ishiguro, T.; Adachi, S.; et al. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Sci. Rep. 2019, 9, 17808. [Google Scholar] [CrossRef] [PubMed]
- Nagaraja, A.K.; Creighton, C.J.; Yu, Z.; Zhu, H.; Gunaratne, P.H.; Reid, J.G.; Olokpa, E.; Itamochi, H.; Ueno, N.T.; Hawkins, S.M.; et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol. 2010, 24, 447–463. [Google Scholar] [CrossRef] [PubMed]
- Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834–838. [Google Scholar] [CrossRef] [PubMed]
- Hendrikse, C.S.E.; Theelen, P.M.M.; van der Ploeg, P.; Westgeest, H.M.; Boere, I.A.; Thijs, A.M.J.; Ottevanger, P.B.; van de Stolpe, A.; Lambrechts, S.; Bekkers, R.L.M.; et al. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. Gynecol. Oncol. 2023, 171, 83–94. [Google Scholar] [CrossRef] [PubMed]
- Therachiyil, L.; Anand, A.; Azmi, A.; Bhat, A.; Korashy, H.M.; Uddin, S. Role of RAS signaling in ovarian cancer. F1000Research 2022, 11, 1253. [Google Scholar] [CrossRef] [PubMed]
- Bendifallah, S.; Suisse, S.; Puchar, A.; Delbos, L.; Poilblanc, M.; Descamps, P.; Golfier, F.; Jornea, L.; Bouteiller, D.; Touboul, C.; et al. Salivary MicroRNA Signature for Diagnosis of Endometriosis. J. Clin. Med. 2022, 11, 612. [Google Scholar] [CrossRef] [PubMed]
- Wu, L.; Zheng, K.; Yan, C.; Pan, X.; Liu, Y.; Liu, J.; Wang, F.; Guo, W.; He, X.; Li, J.; et al. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma. BMC Cancer. 2019, 19, 843. [Google Scholar] [CrossRef]
- Liu, Y.N.; Yin, J.J.; Abou-Kheir, W.; Hynes, P.G.; Casey, O.M.; Fang, L.; Yi, M.; Stephens, R.M.; Seng, V.; Sheppard-Tillman, H.; et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumourigenesis via Slug-independent mechanisms. Oncogene 2013, 17, 296–306. [Google Scholar] [CrossRef]
- Yang, Y.M.; Yang, W.X. Epithelial-to-mesenchymal transition in the development of endometriosis. Oncotarget 2017, 8, 41679–41689. [Google Scholar] [CrossRef]
- Toda, H.; Seki, N.; Kurozumi, S.; Shinden, Y.; Yamada, Y.; Nohata, N.; Moriya, S.; Idichi, T.; Maemura, K.; Fujii, T.; et al. RNA-Sequence-based microRNA expression signature in breast cancer: Tumour-suppressive miR-101-5p regulates molecular pathogenesis. Mol. Oncol. 2020, 14, 426–446. [Google Scholar] [CrossRef]
- Shimono, Y.; Zabala, M.; Cho, R.W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, M.; Liu, H.; Panula, S.P.; Chiao, E.; et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138, 592–603. [Google Scholar] [CrossRef] [PubMed]
- Klicka, K.; Grzywa, T.M.; Mielniczuk, A.; Klinke, A.; Włodarski, P.K. The role of miR-200 family in the regulation of hallmarks of cancer. Front. Oncol. 2022, 12, 965231. [Google Scholar] [CrossRef] [PubMed]
- Ibrahim, F.F.; Jamal, R.; Syafruddin, S.E.; Ab Mutalib, N.S.; Saidin, S.; MdZin, R.R.; Hossain Mollah, M.M.; Mokhtar, N.M. MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer. J. Ovarian. Res. 2015, 12, 56. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Zhang, X.; Huang, Y.; Zhang, Q.; Zhou, J.; Zhang, X.; Wang, X. miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. Oncol. Lett. 2019, 17, 1453–1460. [Google Scholar] [CrossRef]
- Yang, D.; Zhan, M.; Chen, T.; Chen, W.; Zhang, Y.; Xu, S.; Yan, J.; Huang, Q.; Wang, J. miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer. Sci. Rep. 2017, 7, 43109. [Google Scholar] [CrossRef] [PubMed]
- Peng, B.; Theng, P.Y.; Le, M.T.N. Essential functions of miR-125b in cancer. Cell. Prolif. 2021, 54, e12913. [Google Scholar] [CrossRef]
- Hirakawa, T.; Nasu, K.; Abe, W.; Aoyagi, Y.; Okamoto, M.; Kai, K.; Takebayashi, K.; Narahara, H. miR-503, a microRNA epigenetically repressed in endometriosis, induces apoptosis and cell-cycle arrest and inhibits cell proliferation, angiogenesis, and contractility of human ovarian endometriotic stromal cells. Hum. Reprod. 2016, 31, 2587–2597. [Google Scholar] [CrossRef]
- Park, G.B.; Kim, D. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells. Neoplasia 2019, 21, 206–215. [Google Scholar] [CrossRef]
- Hudelist, G.; Valentin, L.; Saridogan, E.; Condous, G.; Malzoni, M.; Roman, H.; Jurkovic, D.; Keckstein, J. What to choose and why to use—A critical review on the clinical relevance of rASRM, EFI and Enzian classifications of endometriosis. Facts Views Vis. Obgyn. 2021, 13, 331–338. [Google Scholar] [CrossRef]
- Suryawanshi, S.; Vlad, A.M.; Lin, H.M.; Mantia-Smaldone, G.; Laskey, R.; Lee, M.; Lin, Y.; Donnellan, N.; Klein-Patel, M.; Lee, T.; et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin. Cancer Res. 2013, 1, 1213–1224. [Google Scholar] [CrossRef] [PubMed]
- Gadducci, A.; Multinu, F.; Cosio, S.; Carinelli, S.; Ghioni, M.; Aletti, G.D. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynaecol. Oncol. 2021, 162, 741–750. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, N.; Leidinger, P.; Becker, K.; Backes, C.; Fehlmann, T.; Pallasch, C.; Rheinheimer, S.; Meder, B.; Stähler, C.; Meese, E.; et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016, 5, 3865–3877. [Google Scholar] [CrossRef] [PubMed]
1 EC n = 47 | 2 EOC n = 26 | 3 HGSOC n = 29 | 4 CG n = 33 | p | |
---|---|---|---|---|---|
Age (years) | 38.92 ± 13.51 | 56.80 ± 12.46 | 64.31 ± 11.28 | 58.10 ± 12.52 | <0.05 |
BMI (kg/m2) | 25.21 ± 3.91 | 27.38 ± 4.25 | 28.70 ± 3.19 | 27.55 ± 4.05 | >0.05 |
CA125 (U/mL) | 63.52 ± 68.90 | 143.18 ± 118.81 | 884.47 ± 922.59 | n/a | <0.05 |
Deliveries | 0 | 1.5 | 2 | 2 | <0.05 |
Miscarriages | 0 | 0 | 0 | 0 | >0.05 |
Hypertension | 13% | 20% | 19% | 18% | >0.05 |
Smoking | 14% | 16% | 18% | 18% | >0.05 |
Stage | I | II | III | |
---|---|---|---|---|
Cancer | ||||
EOC (n) | 15 | 5 | 6 | |
HGSOC (n) | 4 | 9 | 16 |
Name in Database | Accession Number |
---|---|
hsa-miR-125b-1-3p | MIMAT0004592 |
hsa-miR-31-3p | MIMAT0004504 |
hsa-miR-1-3p | MIMAT0000123 |
hsa-miR-191-5p | MIMAT0000440 |
hsa-miR-200b-3p | MIMAT0000318 |
hsa-miR-502-5p | MIMAT0002873 |
hsa-miR-503-5p | MIMAT0002874 |
hsa-miR-548d-5p | MIMAT0004812 |
1 EC | 2 EOC | 3 HGSOC | 4 CG | p Value | |
---|---|---|---|---|---|
miR1-3p | 2.74 | 3.71 | 4.26 | 2.43 | 0.0106 |
miR125b-1-3p | 6.22 | 11.16 | 9.95 | 5.31 | <0.0001 |
miR200b-3p | 5.60 | −2.46 | −1.31 | 7.69 | <0.0001 |
miR31-3p | 8.75 | 7.48 | 7.37 | 13.40 | <0.0001 |
miR-502-5p | 3.74 | 4.50 | 4.39 | 3.71 | 0.0697 |
miR-503-5p | 2.98 | 4.42 | 5.26 | 3.82 | <0.0001 |
miR-548d-5p | 6.55 | 5.37 | 5.62 | 6.99 | 0.0601 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szubert, M.; Nowak-Glück, A.; Domańska-Senderowska, D.; Szymańska, B.; Sowa, P.; Rycerz, A.; Wilczyński, J.R. miRNA Expression Profiles in Ovarian Endometriosis and Two Types of Ovarian Cancer—Endometriosis-Associated Ovarian Cancer and High-Grade Ovarian Cancer. Int. J. Mol. Sci. 2023, 24, 17470. https://doi.org/10.3390/ijms242417470
Szubert M, Nowak-Glück A, Domańska-Senderowska D, Szymańska B, Sowa P, Rycerz A, Wilczyński JR. miRNA Expression Profiles in Ovarian Endometriosis and Two Types of Ovarian Cancer—Endometriosis-Associated Ovarian Cancer and High-Grade Ovarian Cancer. International Journal of Molecular Sciences. 2023; 24(24):17470. https://doi.org/10.3390/ijms242417470
Chicago/Turabian StyleSzubert, Maria, Anna Nowak-Glück, Daria Domańska-Senderowska, Bożena Szymańska, Piotr Sowa, Aleksander Rycerz, and Jacek R. Wilczyński. 2023. "miRNA Expression Profiles in Ovarian Endometriosis and Two Types of Ovarian Cancer—Endometriosis-Associated Ovarian Cancer and High-Grade Ovarian Cancer" International Journal of Molecular Sciences 24, no. 24: 17470. https://doi.org/10.3390/ijms242417470